Who
Bob Oliver
Director
Company insider
Files Form 4 as: Director, Exelixis; Director, Immunomedics.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $3.3M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 8 Jan 2017
- Last trade
- 27 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $175K9,088 at $19.28 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $396K9,088 at $43.61 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $929K21,162 at $43.90 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,088 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,088 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $175K9,088 at $19.28 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $396K9,088 at $43.61 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $929K21,162 at $43.90 | filing |
| 17 Nov 2025filed 19 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —1,044 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 25 Feb 2025filed 26 Feb 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,147 at $0.00 | filing |
| 25 Feb 2025filed 26 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $292K15,147 at $19.28 | filing |
| 25 Feb 2025filed 26 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $695K18,647 at $37.25 | filing |
| 31 May 2024filed 4 Jun 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —18,838 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,353 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —18,176 at $0.00 | filing |
| 8 Jan 2017filed 12 Jan 2017 | Immunomedicsoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Bob Oliver; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.